TNGX TANGO THERAPEUTICS INC

Tango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

Tango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a virtual panel on synthetic lethality in cancer therapeutics at the 13th Annual Wedbush PacGrow Healthcare Conference on Tuesday, August 9 at 12:00 PM ET.

A live webcast of the event will be available under the "Events & Presentations" tab on the “Investors” page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.

About Tango Therapeutics

Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit .

Investor Contact:

Sam Martin/Michael Barron

Argot Partners

Media Contact:

Joshua R. Mansbach

Argot Partners



EN
02/08/2022

Underlying

TNGXTANGO THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TANGO THERAPEUTICS INC

 PRESS RELEASE
Free
TNGX TANGO THERAPEUT...

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Ru...

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective February 2, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 367,500 shares of its common stock and 60,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan. The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an ...

14h / 9m 1 EN
 PRESS RELEASE
Free
TNGX TANGO THERAPEUT...

Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial...

Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential of vopimetostat as the preferred PRMT5 inhibitor for combination with RAS targeted therapies in oncology Cash position of $343 million as of December 31, 2025, with runway into 2028 b...

March 5, 2026 1 EN
 PRESS RELEASE
Free
TNGX TANGO THERAPEUT...

Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and...

Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial markets. The company does not intend to hold a conference call. Additionally, Tango Therapeutics management is scheduled to participate in three upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston Corporate presentation on Wed...

February 18, 2026 1 EN
 PRESS RELEASE
Free
TNGX TANGO THERAPEUT...

Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: ...

Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 2:00 PM EST. The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webca...

February 3, 2026 1 EN
 PRESS RELEASE
Free
TNGX TANGO THERAPEUT...

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, ...

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately – BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber...

January 8, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch